Pharma & Biotech Global Week in Review 13 July 2011 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

Tenofovir, Emtricitabine, Elvitegravir, Cobicistat and combination product Quad – Global: Medicines Patent Pool boosts HIV drug prospects with first license (IP Watch) (KEI) (Spicy IP) (GenericsWeb)

Mucinex (Guaifenesin) – US: File history disclaimer dooms Reckitt Benckiser at CAFC: Reckitt Benckiser v Watson Laboratories (IPBiz) (Patent Docs) (GenericsWeb)

Multaq (Dronedarone) – Brazil: INPI did it again – pipeline mechanism – 1ª Turma do Tribunal Regional Federal da 2ª Região unanimously upholds decision keeping a pharmaceutical product in the public domain (IP tango)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

Trans-Pacific Partnership Agreement: Did US move threaten public health? (IP Watch)

BRIC health ministers’ meeting – Beijing declaration (KEI)

“Lilly’s pipeline remains incapable of replacing patent-related losses” (IPBiz)

A new book – and a competition! (The SPC Blog)

Doha+10: On November 14, 2011, a meeting at WIPO in Geneva to discuss the Doha Declaration (KEI)

Docs at BIO: Session on IP challenges for personalised medicine (Patent Docs)

France to reform its pharmaceutical regulatory system… with possible global implications! (IP Whiteboard)

France: Court of Appeal, Paris dismisses Teva’s third party appeal against decision of French Patent Office Director (EPLAW)

India: UNAIDS praises India’s vow not to negotiate away generics (IP Watch)

Kenya: Weekend cuttings – Kenya step up efforts to fight counterfeiting (Afro-IP)

Taiwan’s translational research (or lack thereof) (BIOtechNOW)

US: Myriad Genetics’ actions justify a ban on gene patents? (BIOtechNOW)

US: PTO agrees to reexamine broad codon-optimization patents (Holman’s Biotech IP Blog)

US: Inherently incomprehensible: Does the CAFC’s view of inherency in In Re Kao spell the end of second medical use patents in the USA? (America-Israel Patent Law)

US: Will the dog days of summer offer a reprieve to FDA and the regulated industry (and your bleary-eyed bloggers)? Doubtful (FDA Law Blog)

US: Joint citizen petition asks FDA for clarity on off-label use manufacturer-communications (FDA Law Blog)

 

Products

Allegra (Fexofenadine) – US: Sanofi settles with Actavis in Allegra suit (Patent Docs)

Aloxi (Palonosetron) – US: Roche sues Teva, Sandoz, Dr Reddy over generic Aloxi (GenericsWeb)

Amrix (Cyclobenzaprine) – US: CAFC changes course, denies stay of injunction of Mylan’s generic Amrix sales: In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litigation (Orange Book Blog) (IPBiz)

Asacol (Mesalazine) – US: CAFC allows Par’s appeal of Asacol declaratory judgment decision to proceed: Medeva Pharma Suisse v Par Pharmaceutical (Orange Book Blog)

Carbatrol (Carbamazepine) – US: New Jersey District Court denies preliminary injunction motion in generic Carbatrol pre-MMA 180-day exclusivity case; an appeal quickly follows (FDA Law Blog)

Edluar (Zolpidem) – US: Orexo files patent infringement complaint against Mylan in response to Para IV certification (Patent Docs)

Effexor (Venlafaxine) – US: Wyeth and Intellipharmaceutics settle Effexor XR patent litigation (Patent Docs)

Enterisol (Ileitis) – US: Intervet files patent infringement suit against Boehringer Ingelheim Vetmedica over Enterisol product (Patent Docs)

Ilaris (Canakinumab) – US: Priority review vouchers – Not much bang for the buck (FDA Law Blog)

Lipitor (Atorvastatin) – Grape-flavoured Lipitor get the go-ahead for children (The SPC Blog)

Lyrica (Pregabalin) – US: Pfizer sues Apotex over generic version of nerve pain drug Lyrica (GenericsWeb)

Lysteda (Tranexamic) – US: Ferring files patent infringement complaint against Watson Pharmaceuticals following Para IV challenge (Patent Docs)

Mucinex (Guaifenesin) – US: File history disclaimer dooms Reckitt Benckiser at CAFC: Reckitt Benckiser v Watson Laboratories (IPBiz) (Patent Docs) (GenericsWeb)

Multaq (Dronedarone) – Brazil: INPI did it again – pipeline mechanism – 1ª Turma do Tribunal Regional Federal da 2ª Região unanimously upholds decision keeping a pharmaceutical product in the public domain (IP tango)

Nexium (Esomeprazole) – Netherlands: District Court of The Hague finds AstraZeneca’s patent inventive, sufficiently disclosed and with no added matter: Sandoz/Hexal and Stada/Centrafarm v AstraZeneca (EPLAW)

Tenofovir, Emtricitabine, Elvitegravir, Cobicistat and combination product Quad – Global: Medicines Patent Pool boosts HIV drug prospects with first license (IP Watch) (KEI) (Spicy IP) (GenericsWeb)

Tricor (Fenofibrate) – US: Elan and Abbott drop Tricor patent suit with Teva (Patent Docs)

Vigamox (Moxifloxacin) – US: Alcon files patent infringement complaint against Lupin in response to Para IV certification filing (Patent Docs)

Vyvanse (Lisdexamfetamine) – US: Shire files patent infringement suits against Roxane, Sandoz and Amneal Pharmaceuticals following Para IV certification filing (Patent Docs) (GenericsWeb)

Yasmin (Ethinyl estradiol, Drospirenone) – EU: Bayer’s Yasmin to face EU generics this year (GenericsWeb)

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: